분산형 임상시험 시장 규모 조사 : 시험 설계별, 적응증별, 구성요소별, 최종 사용자별, 지역별 전망(2022-2032년)

세계 분산형 임상시험 시장은 2023년 약 93억 달러 규모로 평가되며, 2024-2032년의 예측 기간 동안 15.40% 이상의 견조한 성장률을 보일 것으로 예상됩니다.

분산형 임상시험(DCT)은 임상연구의 전망에 혁명을 가져왔고, 임상시험 수행 방식에 패러다임의 전환을 가져왔습니다. 이 혁신적인 접근 방식은 디지털 헬스 기술을 활용하여 원격 모니터링과 데이터 수집을 가능케 함으로써 참여자의 편의성을 높이고 환자의 다양성을 확대하는 데 기여하고 있습니다. 이러한 시장 성장의 원동력은 의약품 개발 기간을 단축하고, 비용을 절감하며, 더 많은 환자들이 다양한 치료법에 접근할 수 있도록 하는 것이 필수적이라는 점을 꼽을 수 있습니다.

임상시험의 세계화는 다양한 지역에 걸친 광범위한 도달 범위로 인해 헬스케어 부문의 변화의 시기를 강조하고 있습니다. 제약회사와 생명공학 기업들은 다양한 인구 집단으로부터 종합적인 데이터를 수집하기 위해 임상시험에 많은 투자를 하고 있습니다. 임상시험 참여는 유전적 배경과 사회경제적 배경에 따른 치료 효과에 대한 이해를 높이고, 잠재적인 부작용과 약물 반응에 대한 중요한 통찰력을 제공합니다. 또한, 규제 조화로 인해 여러 국가에 걸친 승인 절차가 간소화되어 중복된 노력을 줄이고 획기적인 치료제 시장 진입을 가속화할 수 있게 되었습니다. 그러나 데이터 프라이버시 및 보안, 규제 준수에 대한 우려는 2024-2032년의 예측 기간 동안 전체 시장 수요를 저해할 것으로 보입니다.

세계 분산형 임상시험 시장 조사에서 고려된 주요 지역으로는 아시아태평양, 북미, 유럽, 유럽, 라틴아메리카 및 기타 지역이 포함되며, 2023년 북미는 선진화된 헬스케어 인프라와 주요 제약사의 존재로 인해 지역별로 시장 점유율을 차지할 것으로 예상됩니다. FDA와 같은 규제 기관은 DCT에 대한 지지를 강화하고 있으며, 이러한 시험의 채택을 촉진하기 위한 가이드라인과 프레임워크를 제공합니다. 이러한 규제 환경은 제약사들이 탈중앙화 모델을 모색하도록 장려하고 있습니다. 또한, 아시아태평양 시장은 2024년부터 2032년까지 예측 기간 동안 가장 빠른 속도로 발전할 것으로 예상됩니다.

목차

제1장 세계의 분산화 임상시험 시장 주요 요약

• 세계의 분산화 임상시험 시장 규모 및 예측(2022-2032년)
• 지역별 개요
• 부문별 개요
  • 시험 디자인별
  • 적응증별
  • 컴포넌트별
  • 최종사용자별
• 주요 동향
• 경기후퇴의 영향
• 애널리스트의 결론 및 제안

제2장 세계의 분산화 임상시험 시장 정의와 조사의 전제조건

• 조사 목적
• 시장의 정의
• 조사의 전제조건
  • 포함과 제외
  • 제한 사항
  • 공급측 분석
    • 가용성
    • 인프라
    • 규제 환경
    • 시장 경쟁
    • 경제성(소비자 시점)
  • 수요측 분석
    • 규제 프레임워크
    • 기술 진보
    • 친환경
    • 소비자 의식과 수용
• 조사 방법
• 조사 대상년도
• 통화 환산율

제3장 세계의 분산화 임상시험 시장 역학

• 시장 성장 촉진요인 ]
• 시장이 해결해야 할 과제
• 시장 기회

  제4장 세계의 분산화 임상시험 시장 산업 분석

  • Porter's Five Forces 모델
    • 공급 기업의 교섭력
    • 바이어의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계
    • Porter's Five Forces 모델에 대한 미래적 접근
    • Porter's Five Forces의 영향 분석
  • PESTEL 분석
    • 정치
    • 경제
    • 사회
    • 기술
    • 환경
    • 법률
  • 주요 투자 기회
  • 주요 성공 전략
  • 파괴적 동향
  • 업계 전문가의 견해
  • 애널리스트의 결론 및 제안

  제5장 세계의 분산화 임상시험 시장 규모와 예측 : 시험 디자인별, 2022년-2032년

  • 부문 대시보드
  • 세계의 분산화 임상시험 시장 : 매출 동향 분석, 2022년·2032년
    • 개입 시험
    • 관찰 연구
    • 확장 액세스

  제6장 세계의 분산화 임상시험 시장 규모와 예측 : 적응증별, 2022년-2032년

  • 부문 대시보드
  • 세계의 분산화 임상시험 시장 : 매출 동향 분석, 2022년·2032년
    • 종양학
    • 순환기
    • 면역학
    • 호흡기
    • 기타

  제7장 세계의 분산화 임상시험 시장 규모와 예측 : 컴포넌트별, 2022년-2032년

  • 부문 대시보드
  • 세계의 분산화 임상시험 시장 : 매출 동향 분석, 2022년·2032년
    • 모바일 헬스케어
    • 원격의료
    • 웨어러블 디바이스
    • 웹 기반 기술
    • 기타

  제8장 세계의 분산화 임상시험 시장 규모와 예측 : 최종사용자별, 2022년-2032년

  • 부문 대시보드
  • 세계의 분산화 임상시험 시장 : 매출 동향 분석, 2022년·2032년
    • 제약 및 바이오의약품 기업
    • CRO
    • 기타

  제9장 세계의 분산화 임상시험 시장 규모와 예측 : 지역별, 2022년-2032년

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 사우디아라비아
    • 남아프리카공화국
    • 기타 중동 및 아프리카

  제10장 경쟁 정보

  • 주요 기업의 SWOT 분석
  • 주요 시장 전략
  • 기업 개요
    • ICON plc
      • 주요 정보
      • 개요
      • 재무(데이터 입수가 가능한 경우)
      • 제품 개요
      • 시장 전략
    • Medpace Holdings, Inc.
    • Parexel International Corporation
    • PPD, Inc.
    • Covance Inc.
    • LabCorp Drug Development
    • PRA Health Sciences
    • Syneos Health
    • IQVIA Holdings Inc.
    • Charles River Laboratories International, Inc.

  제11장 조사 과정

  • 조사 과정
    • 데이터 마이닝
    • 분석
    • 시장 추정
    • 검증
    • 출판
  • 조사 속성
  LSH 24.07.24

  Global Decentralised Clinical Trials Market is valued at approximately USD 9.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.40% over the forecast period 2024-2032. Decentralised Clinical Trials (DCTs) has revolutionized the landscape of clinical research, offering a paradigm shift in how trials are conducted. This innovative approach leverages digital health technologies, enabling remote monitoring and data collection, thus enhancing participant convenience and broadening patient diversity. The driving force behind this market surge includes the imperative to accelerate drug development timelines, mitigate costs, and increase the accessibility of diverse treatments to among large number of patients.

  The globalization of clinical trials underscores a transformative era in the healthcare sector, driven by an extensive reach across various geographies. Pharmaceutical and biotech companies are heavily investing in these trials to garner comprehensive data from diverse demographic groups. This inclusivity in clinical trials fosters a deeper understanding of treatment efficacies across different genetic and socio-economic backgrounds, unveiling critical insights into potential side effects and drug responses. Moreover, regulatory harmonization has streamlined approval processes across multiple countries, reducing redundant efforts and expediting the introduction of breakthrough therapies to the market. However, concerns regarding data privacy and security and regulatory compliance are going to impede the overall demand for the market during the forecast period 2024-2032.

  The key regions considered for the Global Decentralised Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the dominating among regional market in terms of revenue owing to factors such as advanced healthcare infrastructure and the presence of major pharmaceutical companies. Regulatory bodies such as the FDA have been increasingly supportive of DCTs, providing guidelines and frameworks that facilitate the adoption of these trials. This regulatory environment encourages pharmaceutical companies to explore decentralized models. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.

  Major market players included in this report are:

  • ICON plc
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • PPD, Inc.
  • Covance Inc.
  • LabCorp Drug Development
  • PRA Health Sciences
  • Syneos Health
  • IQVIA Holdings Inc.
  • Charles River Laboratories International, Inc

  The detailed segments and sub-segment of the market are explained below:

  By Study Design

  • Interventional
  • Observational
  • Expanded Access

  By Indication

  • Oncology
  • Cardiovascular
  • Immunology
  • Respiratory
  • Others

  By Component

  • Mobile Healthcare
  • Telemedicine
  • Wearable Devices
  • Web-based Technology
  • Others

  By End-users

  • Pharmaceutical and Biopharmaceutical Companies
  • CROs
  • Others

  By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

  Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

  Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market

  Table of Contents

  Chapter 1. Global Decentralised Clinical Trials Market Executive Summary

  • 1.1. Global Decentralised Clinical Trials Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Study Design
    • 1.3.2. By Indication
    • 1.3.3. By Component
    • 1.3.4. By End-users
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

  Chapter 2. Global Decentralised Clinical Trials Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

  Chapter 3. Global Decentralised Clinical Trials Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Accelerated Drug Development
    • 3.1.2. Cost Reduction
    • 3.1.3. Access to Diverse Populations
  • 3.2. Market Challenges
    • 3.2.1. Data Privacy and Security Concerns
    • 3.2.2. Regulatory Compliance
  • 3.3. Market Opportunities
    • 3.3.1. Technological Advancements
    • 3.3.2. Expansion in Emerging Markets
    • 3.3.3. Increased Collaboration and Data Exchange

  Chapter 4. Global Decentralised Clinical Trials Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

  Chapter 5. Global Decentralised Clinical Trials Market Size & Forecasts by Study Design 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Decentralised Clinical Trials Market: Study Design Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Interventional
    • 5.2.2. Observational
    • 5.2.3. Expanded Access

  Chapter 6. Global Decentralised Clinical Trials Market Size & Forecasts by Indication 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Decentralised Clinical Trials Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Oncology
    • 6.2.2. Cardiovascular
    • 6.2.3. Immunology
    • 6.2.4. Respiratory
    • 6.2.5. Others

  Chapter 7. Global Decentralised Clinical Trials Market Size & Forecasts by Component 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Decentralised Clinical Trials Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Mobile Healthcare
    • 7.2.2. Telemedicine
    • 7.2.3. Wearable Devices
    • 7.2.4. Web-based Technology
    • 7.2.5. Others

  Chapter 8. Global Decentralised Clinical Trials Market Size & Forecasts by End-users 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global Decentralised Clinical Trials Market: End-users Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 8.2.1. Pharmaceutical and Biopharmaceutical Companies
    • 8.2.2. CROs
    • 8.2.3. Others

  Chapter 9. Global Decentralised Clinical Trials Market Size & Forecasts by Region 2022-2032

  • 9.1. North America Decentralised Clinical Trials Market
    • 9.1.1. U.S. Decentralised Clinical Trials Market
      • 9.1.1.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.1.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.1.1.3. Component breakdown size & forecasts, 2022-2032
      • 9.1.1.4. End-users breakdown size & forecasts, 2022-2032
    • 9.1.2. Canada Decentralised Clinical Trials Market
      • 9.1.2.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.1.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.1.2.3. Component breakdown size & forecasts, 2022-2032
      • 9.1.2.4. End-users breakdown size & forecasts, 2022-2032
  • 9.2. Europe Decentralised Clinical Trials Market
    • 9.2.1. U.K. Decentralised Clinical Trials Market
      • 9.2.1.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.1.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.1.4. End-users breakdown size & forecasts, 2022-2032
    • 9.2.2. Germany Decentralised Clinical Trials Market
      • 9.2.2.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.2.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.2.4. End-users breakdown size & forecasts, 2022-2032
    • 9.2.3. France Decentralised Clinical Trials Market
      • 9.2.3.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.3.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.3.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.3.4. End-users breakdown size & forecasts, 2022-2032
    • 9.2.4. Spain Decentralised Clinical Trials Market
      • 9.2.4.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.4.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.4.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.4.4. End-users breakdown size & forecasts, 2022-2032
    • 9.2.5. Italy Decentralised Clinical Trials Market
      • 9.2.5.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.5.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.5.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.5.4. End-users breakdown size & forecasts, 2022-2032
    • 9.2.6. Rest of Europe Decentralised Clinical Trials Market
      • 9.2.6.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.2.6.2. Indication breakdown size & forecasts, 2022-2032
      • 9.2.6.3. Component breakdown size & forecasts, 2022-2032
      • 9.2.6.4. End-users breakdown size & forecasts, 2022-2032
  • 9.3. Asia-Pacific Decentralised Clinical Trials Market
    • 9.3.1. China Decentralised Clinical Trials Market
      • 9.3.1.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.1.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.1.4. End-users breakdown size & forecasts, 2022-2032
    • 9.3.2. India Decentralised Clinical Trials Market
      • 9.3.2.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.2.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.2.4. End-users breakdown size & forecasts, 2022-2032
    • 9.3.3. Japan Decentralised Clinical Trials Market
      • 9.3.3.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.3.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.3.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.3.4. End-users breakdown size & forecasts, 2022-2032
    • 9.3.4. Australia Decentralised Clinical Trials Market
      • 9.3.4.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.4.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.4.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.4.4. End-users breakdown size & forecasts, 2022-2032
    • 9.3.5. South Korea Decentralised Clinical Trials Market
      • 9.3.5.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.5.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.5.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.5.4. End-users breakdown size & forecasts, 2022-2032
    • 9.3.6. Rest of Asia Pacific Decentralised Clinical Trials Market
      • 9.3.6.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.3.6.2. Indication breakdown size & forecasts, 2022-2032
      • 9.3.6.3. Component breakdown size & forecasts, 2022-2032
      • 9.3.6.4. End-users breakdown size & forecasts, 2022-2032
  • 9.4. Latin America Decentralised Clinical Trials Market
    • 9.4.1. Brazil Decentralised Clinical Trials Market
      • 9.4.1.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.4.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.4.1.3. Component breakdown size & forecasts, 2022-2032
      • 9.4.1.4. End-users breakdown size & forecasts, 2022-2032
    • 9.4.2. Mexico Decentralised Clinical Trials Market
      • 9.4.2.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.4.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.4.2.3. Component breakdown size & forecasts, 2022-2032
      • 9.4.2.4. End-users breakdown size & forecasts, 2022-2032
    • 9.4.3. Rest of Latin America Decentralised Clinical Trials Market
      • 9.4.3.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.4.3.2. Indication breakdown size & forecasts, 2022-2032
      • 9.4.3.3. Component breakdown size & forecasts, 2022-2032
      • 9.4.3.4. End-users breakdown size & forecasts, 2022-2032
  • 9.5. Middle East & Africa Decentralised Clinical Trials Market
    • 9.5.1. Saudi Arabia Decentralised Clinical Trials Market
      • 9.5.1.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.5.1.2. Indication breakdown size & forecasts, 2022-2032
      • 9.5.1.3. Component breakdown size & forecasts, 2022-2032
      • 9.5.1.4. End-users breakdown size & forecasts, 2022-2032
    • 9.5.2. South Africa Decentralised Clinical Trials Market
      • 9.5.2.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.5.2.2. Indication breakdown size & forecasts, 2022-2032
      • 9.5.2.3. Component breakdown size & forecasts, 2022-2032
      • 9.5.2.4. End-users breakdown size & forecasts, 2022-2032
    • 9.5.3. Rest of Middle East & Africa Decentralised Clinical Trials Market
      • 9.5.3.1. Study Design breakdown size & forecasts, 2022-2032
      • 9.5.3.2. Indication breakdown size & forecasts, 2022-2032
      • 9.5.3.3. Component breakdown size & forecasts, 2022-2032
      • 9.5.3.4. End-users breakdown size & forecasts, 2022-2032

  Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. ICON plc
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Market Strategies
    • 10.3.2. Medpace Holdings, Inc.
    • 10.3.3. Parexel International Corporation
    • 10.3.4. PPD, Inc.
    • 10.3.5. Covance Inc.
    • 10.3.6. LabCorp Drug Development
    • 10.3.7. PRA Health Sciences
    • 10.3.8. Syneos Health
    • 10.3.9. IQVIA Holdings Inc.
    • 10.3.10. Charles River Laboratories International, Inc.

  Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes